Evidence map›Paper›PMID 40702203›Full record

ArticleAnnals of surgical oncology2025

Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study.

Ellery H Reason, Michael D Aiduk, Amanda L Nash, Susan G R McDuff, Derrick Renner, Rahul Krishna Kollipara, Sandro Satta, Sharlene Velichko, Ekaterina Kalashnikova, Angel A Rodriguez and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ellery H ReasonDuke University School of Medicine, Durham, NC, USA.
Michael D AidukDuke University School of Medicine, Durham, NC, USA.
Amanda L NashDuke Cancer Institute, Duke University, Durham, NC, USA.
Susan G R McDuffDuke Cancer Institute, Duke University, Durham, NC, USA.
Derrick RennerNatera, Inc, Austin, TX, USA.
Rahul Krishna KolliparaNatera, Inc, Austin, TX, USA.
Sandro SattaNatera, Inc, Austin, TX, USA.
Sharlene VelichkoNatera, Inc, Austin, TX, USA.
Ekaterina KalashnikovaNatera, Inc, Austin, TX, USA.
Angel A RodriguezNatera, Inc, Austin, TX, USA.
Minetta C LiuNatera, Inc, Austin, TX, USA.
John H StricklerDuke Cancer Institute, Duke University, Durham, NC, USA.
Juneko E Grilley-OlsonDuke Cancer Institute, Duke University, Durham, NC, USA.
Laura H RosenbergerDuke Cancer Institute, Duke University, Durham, NC, USA. Laura.Rosenberger@duke.edu.ORCID http://orcid.org/0000-0002-6829-6747

Funding

Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

backgroundMalignant phyllodes tumors (MPT) are biologically aggressive breast neoplasms, with high local and distant recurrence rates and a median survival of 12 months when metastatic. With a disease-free interval often less than 2 years, circulating tumor DNA (ctDNA) may allow for earlier identification of patients with MPT at risk for recurrence. Here, we aim to determine the feasibility of detecting ctDNA in (1) patients with known, active metastatic disease and (2) patients with nonmetastatic MPT prior to surgical resection. PATIENTS AND

methodsNine patients with MPT were identified from an institutional review board-approved prospective phyllodes tumors registry and tumor biorepository. Whole exome sequencing (WES) was performed on tumor tissue and matched blood samples for each patient. A tumor informed assay with 16 patient-specific somatic variants was used to detect ctDNA in corresponding plasma samples.

resultsOf the nine patients included (median age: 48.0 years), 67% (n = 6) had known untreated metastatic disease, and 33% (n = 3) did not have metastatic disease at the time of tissue collection. All patients (n = 6/6) with metastatic disease had detectable ctDNA (mean 119 mean tumor molecules (MTM)/mL). Furthermore, 33% (n = 1/3) of nonmetastatic patients had detectable ctDNA (mean 0.2 MTM/mL) before definitive surgery. The most common mutations revealed by tumor WES were in TERT, TP53, and NF1.

conclusionsctDNA is reliably detected in patients with known metastatic disease and may enable monitoring for distant relapses after primary surgical resection. These data will inform a prospective study design to determine the efficacy and utility of ctDNA for MPT as well as its potential for monitoring response to systemic therapies.

Indexed as

Biomarkers, TumorBreast NeoplasmsCirculating Tumor DNANeoplasm Recurrence, LocalPhyllodes TumorAdultExome SequencingFeasibility StudiesFemaleFollow-Up StudiesHumansMiddle AgedMutationPrognosisProspective StudiesSurvival RateBiomarkers, TumorCirculating Tumor DNACirculating tumor DNActDNAMalignant phyllodes tumorMetastatic diseaseMolecular residual disease

Identifiers

PMID40702203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.